PMID: 9546120Apr 18, 1998Paper

Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan

Helicobacter
J SuzukiT Fujita

Abstract

Multiple regimens for the eradication of Helicobacter pylori have been tested, but the best therapy has not been determined yet. To determine the efficacy of a new triple agent regimen using a combination of lansoprazole, amoxicillin, and clarithromycin against Helicobacter pylori (H. pylori), and to examine H. pylori resistance to this therapy in ineffective cases. We studied a total of 71 patients infected with H. pylori who had gastric ulcer (n = 37) or duodenal ulcer (n = 34) as confirmed by endoscopy. Patients received 1500 mg amoxicillin, 400 mg clarithromycin and 30 mg lansoprazole for 2 weeks followed by 30 mg lansoprazole for 6 weeks in patients with gastric ulcer or for 4 weeks in those with duodenal ulcer. Endoscopic examination was performed before treatment and at 1 month, 2 months, and 5 months after initiating treatment to check the status of ulceration and H. pylori infection. The eradication rate of H. pylori was 92% (CI, 83-100%) in the gastric ulcer group and 94% (CI, 86-100%) in the duodenal ulcer group at 5 months, as determined by per-protocol analysis. Resistance to clarithromycin was present in 1 of 71 (1%) patients before treatment and in 2 of 5 (40%) patients after treatment. No resistance to amoxicill...Continue Reading

References

Jul 25, 1992·Lancet·R P LoganJ J Misiewicz
Feb 1, 1992·The Journal of Antimicrobial Chemotherapy·G CederbrantA Ljungh
Dec 8, 1990·Lancet·J WeilP H Jones
Sep 1, 1990·Antimicrobial Agents and Chemotherapy·C E HaasJ J Schentag
Sep 1, 1989·Antimicrobial Agents and Chemotherapy·J A García-RodríguezJ L Muñoz Bellido
Jan 19, 1995·The New England Journal of Medicine·J J SungA K Li
Feb 7, 1994·NIH Consensus Statement
Aug 1, 1994·Alimentary Pharmacology & Therapeutics·M T al-AssiD Y Graham

❮ Previous
Next ❯

Citations

Nov 4, 2000·Journal of Gastroenterology and Hepatology·W H WangS K Lam
Dec 6, 2000·Journal of Gastroenterology and Hepatology·K M Fock
Jun 26, 2001·Journal of Gastroenterology and Hepatology·A NagaharaN Sato
Dec 17, 2003·Journal of Gastroenterology and Hepatology·Chieko KatoKazuyuki Suzuki
Oct 2, 2008·Chemical & Pharmaceutical Bulletin·Shoichi HigoYoshiaki Kawashima
Mar 23, 2010·Helicobacter·Masahiro AsakaUNKNOWN Japanese Society for Helicobacter Research
Aug 21, 2002·Expert Opinion on Pharmacotherapy·Harry Hua-Xiang XiaShiu Kum Lam
May 5, 2001·Expert Opinion on Pharmacotherapy·H H XiaS K Lam
Apr 5, 2000·Baillière's Best Practice & Research. Clinical Gastroenterology·P MalfertheinerU Peitz
Mar 12, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E RimbaraM Sasatsu
Nov 19, 2013·Clinics and Research in Hepatology and Gastroenterology·Joon Sung KimJoo Hyun Kim
Jan 31, 2002·World Journal of Gastroenterology : WJG·Hua-Xiang XiaNicholas J Talley
Sep 28, 1999·Scandinavian Journal of Gastroenterology·V EllenriederB Glasbrenner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Campylobacteriosis (ASM)

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.